These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32317400)

  • 61. Riluzole 5 mg/mL oral suspension: for optimized drug delivery in amyotrophic lateral sclerosis.
    Dyer AM; Smith A
    Drug Des Devel Ther; 2017; 11():59-64. PubMed ID: 28053507
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Disease-modifying drug therapies.
    Brooks BR; Sanjak M
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():68-75. PubMed ID: 15512878
    [No Abstract]   [Full Text] [Related]  

  • 63. [Amyotrophic lateral sclerosis].
    Iwanowski L
    Neurol Neurochir Pol; 1999; 33(2):445-50. PubMed ID: 10463257
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Neuroprotective therapy for amyotrophic lateral sclerosis (ALS)].
    Yanagisawa N; Shindo M
    Rinsho Shinkeigaku; 1996 Dec; 36(12):1329-30. PubMed ID: 9128396
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Amyotrophic lateral sclerosis and riluzole use during pregnancy: a case report.
    Scalco RS; Vieira MC; da Cunha Filho EV; Lago EG; da Silva IG; Becker J
    Amyotroph Lateral Scler; 2012 Sep; 13(5):471-2. PubMed ID: 22670879
    [No Abstract]   [Full Text] [Related]  

  • 66. Clinical trials of riluzole in patients with ALS. ALS/Riluzole Study Group-II.
    Miller RG; Bouchard JP; Duquette P; Eisen A; Gelinas D; Harati Y; Munsat TL; Powe L; Rothstein J; Salzman P; Sufit RL
    Neurology; 1996 Oct; 47(4 Suppl 2):S86-90; discussion S90-2. PubMed ID: 8858057
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Limitations of inferences from observational databases in amyotrophic lateral sclerosis: all that glitters is not gold.
    Armon C; Guiloff RJ; Bedlack R
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2002 Sep; 3(3):109-12. PubMed ID: 12495570
    [TBL] [Abstract][Full Text] [Related]  

  • 68. ALS drug development: reflections from the past and a way forward.
    Aggarwal S; Cudkowicz M
    Neurotherapeutics; 2008 Oct; 5(4):516-27. PubMed ID: 19019302
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The use of herbal supplements and alternative therapies by patients with amyotrophic lateral sclerosis (ALS).
    Vardeny O; Bromberg MB
    J Herb Pharmacother; 2005; 5(3):23-31. PubMed ID: 16520295
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Riluzole for amyotrophic lateral sclerosis.
    Drug Ther Bull; 1997 Feb; 35(2):11-2. PubMed ID: 9282413
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Motor neuron disease: systematic reviews of treatment for ALS and SMA.
    Orrell RW
    Br Med Bull; 2010; 93():145-59. PubMed ID: 20015852
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Amyotrophic lateral sclerosis: clinical management and research update.
    Andrews J
    Curr Neurol Neurosci Rep; 2009 Jan; 9(1):59-68. PubMed ID: 19080755
    [TBL] [Abstract][Full Text] [Related]  

  • 73. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247():19-22. PubMed ID: 11200701
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Etiological drug therapy for amyotrophic lateral sclerosis].
    Cintas P
    Rev Neurol (Paris); 2006 Jun; 162 Spec No 2():4S220-4S227. PubMed ID: 17128115
    [TBL] [Abstract][Full Text] [Related]  

  • 75. What has changed with riluzole?
    Meininger V; Lacomblez L; Salachas F
    J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Amyotrophic lateral sclerosis progression: Iran-ALS clinical registry, a multicentre study.
    Shamshiri H; Fatehi F; Davoudi F; Mir E; Pourmirza B; Abolfazli R; Etemadifar M; Harirchian MH; Gharagozli K; Ayromlou H; Basiri K; Zamani B; Rohani M; Sedighi B; Roudbari A; Delavar Kasmaei H; Nikkhah K; Ranjbar Naeini A; Nafissi S
    Amyotroph Lateral Scler Frontotemporal Degener; 2015; 16(7-8):506-11. PubMed ID: 26437387
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic value of decremental responses to repetitive nerve stimulation in ALS patients.
    Wang FC; De Pasqua V; Gérard P; Delwaide PJ
    Neurology; 2001 Sep; 57(5):897-9. PubMed ID: 11552026
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.
    Goyal NA; Mozaffar T
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1541-51. PubMed ID: 24965719
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS.
    Groeneveld GJ; van Kan HJ; Toraño JS; Veldink JH; Guchelaar HJ; Wokke JH; van den Berg LH
    J Neurol Sci; 2001 Oct; 191(1-2):121-5. PubMed ID: 11677002
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rates of progression of weight and forced vital capacity as relevant measurement to adapt amyotrophic lateral sclerosis management for patient Result of a French multicentre cohort survey.
    Clavelou P; Blanquet M; Peyrol F; Ouchchane L; Gerbaud L
    J Neurol Sci; 2013 Aug; 331(1-2):126-31. PubMed ID: 23809193
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.